Workstation CHRONECT Symbiosis Plus 250 bar UHPLC system with online SPE capability

Procurement Summary

The item being procured is a Workstation CHRONECT Symbiosis Plus 250 bar Ultra-High-Performance Liquid Chromatography (UHPLC) system with online SPE capability. This workstation includes multiple pumps, autosampler, injector, SPE analysis compartment and software, and is connected to a mass spectrometer. The workstation is used to remove contamination and isolate chemicals of interest such as per-and polyfluoroalkyl substances (PFAS) and polycyclic aromatic hydrocarbons (PAHs), for the accurate and precise analysis of biospecimens like serum and urine. For example, for urine analysis, the 250-bar system is sufficient because in general urine is available in larger volumes than blood. Also, because of salts and other chemicals present in urine, the 250-bar system is typically best as the smaller diameter systems tend to clog with the particulates in the urine. The Workstation CHRONECT Symbiosis Plus 250 system is the only system fully compatible with Division of Laboratory Systems’ (DLS) current systems and methods and provides an on-line solid phase extraction that can exchange the Solid Phase Extraction (SPE) cartridges in a way that is completely synchronized with the operation of mass spectrometer data collection. The exchange of cartridges is needed to ensure validity of the analytical results because of the complexity of complex biological matrices. The new Symbiosis on-line SPE system with supported software suits the needs of DLS method of systems considered, this is the only workstation that can replace an outdated, non-serviceable make and model instrument that is failing and is currently used in the Organic Analytical Toxicology (OAT) Branch of CDC. Spark Holland dba. iChrom is the only manufacturer and distributor of this specific workstation. This workstation supports methods under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) that are extensively validated and published in peer-reviewed manuscripts using the requested workstation configuration. Any change to the workstation configuration would require extensive time and financial effort to re-validate methodology, thus resulting in significant delays in analysis and reporting of results. For policymakers, health scientists, and the public, access to timely and accurate human data from the approved CLIA methods is critical to track and understand the potential effect on diseases such as cancer and identify and evaluate ways to minimize the health impact of chemicals like PFAS and PAHs.

No

No